DK3013964T3 - Sammensætninger til indføring af rna i celler - Google Patents

Sammensætninger til indføring af rna i celler Download PDF

Info

Publication number
DK3013964T3
DK3013964T3 DK14742474.1T DK14742474T DK3013964T3 DK 3013964 T3 DK3013964 T3 DK 3013964T3 DK 14742474 T DK14742474 T DK 14742474T DK 3013964 T3 DK3013964 T3 DK 3013964T3
Authority
DK
Denmark
Prior art keywords
compositions
cells
introducing rna
rna
introducing
Prior art date
Application number
DK14742474.1T
Other languages
English (en)
Inventor
Christian Koch
Christian Dohmen
Christian Plank
Carsten Rudolph
Original Assignee
Ethris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethris Gmbh filed Critical Ethris Gmbh
Application granted granted Critical
Publication of DK3013964T3 publication Critical patent/DK3013964T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/30Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/0206Polyalkylene(poly)amines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/0206Polyalkylene(poly)amines
    • C08G73/0213Preparatory process
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
DK14742474.1T 2013-06-28 2014-06-27 Sammensætninger til indføring af rna i celler DK3013964T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13174390 2013-06-28
EP13181380 2013-08-22
PCT/EP2014/063756 WO2014207231A1 (en) 2013-06-28 2014-06-27 Compositions for introducing rna into cells

Publications (1)

Publication Number Publication Date
DK3013964T3 true DK3013964T3 (da) 2020-06-15

Family

ID=51224914

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14742474.1T DK3013964T3 (da) 2013-06-28 2014-06-27 Sammensætninger til indføring af rna i celler

Country Status (13)

Country Link
US (1) US12064484B2 (da)
EP (1) EP3013964B1 (da)
JP (1) JP6609246B2 (da)
KR (1) KR102285326B1 (da)
CN (1) CN105579584B (da)
AU (1) AU2014300980B2 (da)
BR (1) BR112015032225B1 (da)
CA (1) CA2916800C (da)
DK (1) DK3013964T3 (da)
EA (1) EA036400B1 (da)
ES (1) ES2810298T3 (da)
WO (1) WO2014207231A1 (da)
ZA (1) ZA201509111B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663360T3 (es) 2011-06-08 2018-04-12 Translate Bio, Inc. Lípidos escindibles
WO2015128030A1 (en) * 2014-02-26 2015-09-03 Ethris Gmbh Compositions for gastrointestinal administration of rna
MX2016014881A (es) 2014-05-14 2017-05-01 Alex Levitzki Man And Holdings Ltd Vectores mejorados de polietilenimina polietilenglicol.
CN113786498A (zh) * 2014-11-10 2021-12-14 埃泽瑞斯公司 通过递送bmp编码rna诱导骨生成
BR122023027721A2 (pt) 2015-06-30 2024-01-30 ethris GmbH Composição
CO2018006699A2 (es) * 2015-12-01 2018-09-20 Spark Therapeutics Inc Métodos escalables para producir un vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspensión sin suero adecuado para uso clínico
RU2751001C2 (ru) * 2016-06-09 2021-07-07 Кьюрвак Аг Гибридные носители для доставки нуклеиновых кислот
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018127382A1 (en) 2017-01-03 2018-07-12 Ethris Gmbh Ornithine transcarbamylase coding polyribonucleotides and formulations thereof
WO2019204451A1 (en) * 2018-04-17 2019-10-24 Carnegie Mellon University Enhanced lipid nanoparticle drug delivery using a negatively charged polymer
CA3098259C (en) * 2018-04-25 2024-02-20 Ethris Gmbh Lipid-based formulations for the delivery of rna
EP3923971B1 (en) 2019-02-14 2023-12-20 ethris GmbH Analyzing the effect of a polyribonucleotide on ciliogenesis
CN111249476B (zh) * 2020-02-19 2023-09-26 深圳厚存纳米药业有限公司 泊洛沙姆和/或泊洛沙胺与脂质组合中性复合物纳米粒
AU2021375281A1 (en) 2020-11-04 2023-06-01 Ethris Gmbh Use of ifn-lambda mrna for treating viral infections
EP4297722A1 (en) 2021-02-26 2024-01-03 Ethris GmbH Formulations for aerosol formation and aerosols for the delivery of nucleic acid
EP4333810A1 (en) * 2021-05-07 2024-03-13 Carnegie Mellon University Lipid nanoparticle-mediated mrna delivery to the pancreas
CN113876639B (zh) * 2021-11-12 2023-08-22 湖北省麦诗特生物科技有限公司 一种含有提高皮肤弹性脂质体的面霜组合物及其制备方法
WO2024042236A1 (en) 2022-08-26 2024-02-29 Ethris Gmbh Stable lipid or lipidoid nanoparticle suspensions
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
WO2024121160A1 (en) 2022-12-05 2024-06-13 Ethris Gmbh Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency
WO2024184626A2 (en) 2023-03-03 2024-09-12 Diosynvax Ltd Coronavirus vaccines

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
JP4538150B2 (ja) * 1998-08-14 2010-09-08 ヴァレンティス,インコーポレイテッド 核酸分子の保護された単一バイアル調製物、インライン混合によってそれを形成する方法、及び関連する生成物及び方法
ATE383331T1 (de) 1998-11-12 2008-01-15 Invitrogen Corp Transportreagentien
DE50006269D1 (de) 1999-06-25 2004-06-03 Stemberger Axel Kombinationen zur einführung von nucleinsäuren in zellen
EP1297169B1 (en) 2000-06-26 2012-08-08 Ethris Gmbh Method for transfecting cells using a magnetic field
CA2445523A1 (en) 2001-04-30 2002-11-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composite scaffolds and methods using same for generating complex tissue grafts
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
CN101124316A (zh) * 2004-12-17 2008-02-13 日东电工株式会社 用于转染真核细胞的固定的可降解阳离子聚合物
WO2006085664A1 (ja) 2005-02-10 2006-08-17 The University Of Tokyo ポリカチオン荷電性ポリマー及び核酸のキャリヤーとしての使用
US20060235459A1 (en) 2005-04-19 2006-10-19 Das Gladwin S Balloon catheters and methods for manufacture
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
SI3611266T1 (sl) 2005-08-23 2023-02-28 The Trustees Of The University Of Pennsylvania Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo
US20120021042A1 (en) * 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
EP1973927B1 (en) 2005-12-15 2013-08-14 Centre National de la Recherche Scientifique - CNRS Cationic oligonucleotides, automated methods for preparing same and their uses
CA2742954C (en) * 2008-11-07 2018-07-10 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2010065660A2 (en) * 2008-12-02 2010-06-10 University Of Utah Research Foundation Biodegradable polydisulfide amines for gene delivery
EP2459231B1 (de) 2009-07-31 2016-06-08 Ethris Gmbh Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
US9168230B2 (en) * 2011-05-26 2015-10-27 University Of South Carolina Tetrary gene delivery system for gene therapy and methods of its use
DE102011114986A1 (de) 2011-09-28 2013-03-28 Ethris Gmbh Sprühsystem
MX354267B (es) 2011-10-03 2018-02-21 Moderna Therapeutics Inc Star Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
WO2014066811A1 (en) * 2012-10-25 2014-05-01 The Johns Hopkins University Bioreducible poly (b-amino ester)s for sirna delivery
RU2649364C2 (ru) * 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
EP2882706A1 (en) * 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof

Also Published As

Publication number Publication date
US12064484B2 (en) 2024-08-20
BR112015032225B1 (pt) 2022-05-17
ES2810298T3 (es) 2021-03-08
KR102285326B1 (ko) 2021-08-04
CN105579584B (zh) 2020-08-28
EP3013964A1 (en) 2016-05-04
JP2016524898A (ja) 2016-08-22
BR112015032225A2 (pt) 2017-07-25
CA2916800C (en) 2022-10-25
JP6609246B2 (ja) 2019-11-20
EA201600044A1 (ru) 2016-06-30
AU2014300980B2 (en) 2020-03-05
CA2916800A1 (en) 2014-12-31
WO2014207231A1 (en) 2014-12-31
ZA201509111B (en) 2021-03-31
AU2014300980A1 (en) 2016-01-07
US20170021036A1 (en) 2017-01-26
EP3013964B1 (en) 2020-05-06
CN105579584A (zh) 2016-05-11
KR20160040524A (ko) 2016-04-14
EA036400B1 (ru) 2020-11-06

Similar Documents

Publication Publication Date Title
DK3013964T3 (da) Sammensætninger til indføring af rna i celler
DK2978419T3 (da) Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf
BR112015027279A8 (pt) métodos e composições para acentuar células t reguladoras cd4+
DK2953634T3 (da) Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
DK3042411T3 (da) Metalunderstøttet fastoxidbrændselscelle
IL290717A (en) Cell preparations derived from dedifferentiated and reprogrammed cells
DK3079658T3 (da) Kammer til indkapsling af secernerende celler
FI11677U1 (fi) Uusiutuva hiilivetykoostumus
DK2686434T3 (da) Fremgangsmåde til reduktion af viskositet i saccharificeringsproces
DK3725778T3 (da) Formuleringer af enzalutamid
DK2941483T3 (da) Fremgangsmåde til at opnå immunstimulerende dendritriske celler
DK3394248T3 (da) Dendritisk cellesammensætning
FI11676U1 (fi) Uusiutuva hiilivetykoostumus
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
DK2941484T3 (da) Fremgangsmåde til at opnå immunsuppressive dendritriske celler
DK2970843T3 (da) Fremgangsmåder til frembringelse af cellebank med høj densitet
DK3242903T3 (da) Sammensætninger til at indføre nukleinsyre i celler
BR112015001562A2 (pt) biotinas e composições
DE112012001867A5 (de) Solarkonzentrator
DE112012003544A5 (de) Solarkonzentrator
DK3003285T3 (en) Fast farmaceutisk dosisform til frigivelse af mindst to aktive farmaceutiske ingredienser i mundhulen
CL2014002030A1 (es) Alfa-amilasa
BR112016009753A2 (pt) método de cultura de células.
DK2825633T3 (da) Fremgangsmåde til dyrkning af E. coli-celler til høj densitet
DK3046628T3 (da) Fremgangsmåder og sammensætninger til fremstilling af hepatocyt-lignende celler